BioNex Therapeutics
Healthy90/100Mid-sizeBiotechnology
About this account
Industry
Biotechnology
Geography
United States (Princeton, NJ) — offices in London, Singapore
Website
bionextherapeutics.comMid-size clinical-stage biopharma, ~450 employees, Series D, 3 Phase 2 compounds + 1 NDA-ready. Focus on biologics for oncology and autoimmune. Working across FDA and EMA.
Relationship health
90/100 · HealthyHow this account's health has moved over the last 5 weeks.
100 pts0 pts
4w ago2w agothis week
How touches have landed
Every logged touch with BioNex Therapeutics, by outcome.
In Progress1100%
Company profile
Not analyzed yet — analyze to qualify its type, ownership and revenue from the web, and the offerings that fit show automatically.
Agent briefing
BioNex Therapeutics is in good shape — healthy, with $250K of open pipeline to grow. It's single-threaded, so widening the relationship would de-risk the deal. Recommended next move: Follow up with BioNex Therapeutics.
HealthHealthy (90/100).
Pipeline1 open deal worth $250K.
ThreadingSingle-threaded on Dr. Priya Mehta — widen the relationship to de-risk.
MomentumLast touch Jul 16, 2026 • 4:58 PM.
Recommended: Follow up with BioNex Therapeutics
Key Contacts
Value PropositionsAI generated
Regulatory Submission Services90% match
Accelerate the upcoming NDA with CTD dossier preparation handled by former FDA/EMA reviewers, cutting prep time 30–40%.
Matched from your Freyr knowledge base
Regulatory Intelligence80% match
Single-pane monitoring across FDA, EMA and 120+ agencies so the team isn't manually tracking guideline shifts during the filing window.
Matched from your Freyr knowledge base
Angles to researchAI generated
Agent-suggested things worth checking before you reach out — verify before you rely on them.
Regulatory
Check for recent Biotechnology guidance that could tighten their submission timelines — a timely reason to reach out.
Hiring
See whether BioNex is hiring in regulatory affairs — a growing team often means more submission workload they may need help with.